Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Total Current Liabilities for 9 consecutive years, with $83.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 58.31% year-over-year to $83.1 million, compared with a TTM value of $83.1 million through Sep 2025, up 58.31%, and an annual FY2024 reading of $60.7 million, up 35.78% over the prior year.
  • Total Current Liabilities was $83.1 million for Q3 2025 at Autolus Therapeutics, up from $68.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $83.1 million in Q3 2025 and bottomed at $28.6 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $52.1 million, with a median of $46.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities fell 15.11% in 2021, then skyrocketed 66.61% in 2025.
  • Year by year, Total Current Liabilities stood at $28.6 million in 2021, then skyrocketed by 62.4% to $46.4 million in 2022, then dropped by 3.51% to $44.7 million in 2023, then skyrocketed by 35.78% to $60.7 million in 2024, then surged by 36.76% to $83.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for AUTL at $83.1 million in Q3 2025, $68.2 million in Q2 2025, and $66.6 million in Q1 2025.